Swiss CDMO Lonza is investing 200 million Swiss francs at its Alpine site in Visp to build a new manufacturing complex for a long-term biopharmaceutical manufacturing...
Swiss CDMO Lonza and China pharma Junshi Biosciences have expanded their biologics collaboration. Lonza will leverage its global network and local operation capabilities...
Lonza Specialty Ingredients (LSI), a division of Swiss-based CDMO Lonza, has sealed a deal to manufacture “high volumes” of Prussian blue materials to be used in energy...
Lonza has signed a definitive agreement to divest its Specialty Ingredients business to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion.
Swiss CDMO Lonza said it intends to unload two of its capsule production sites, at Ploermel, France, and Edinburgh, Scotland, for an undisclosed sum to London-based CDMO...
Swiss CDMO Lonza will build two new suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp site following the signing of a long-term...
Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU...
Swiss CDMO Lonza has inaugurated the first of two planned state-of-the-art, highly-potent API (HPAPI) suites for antibody-drug conjugate (ADC) drug-linker (payload)...
